649
Views
10
CrossRef citations to date
0
Altmetric
Review

Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges

, & ORCID Icon
Pages 1319-1332 | Published online: 31 Dec 2020

References

  • Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. Dermatol Ther. 2019;32(3):e12840. doi:10.1111/dth.12840
  • Diepgen TL, Agner T, Aberer W, et al. Management of chronic hand eczema. Contact Dermatitis. 2007;57(4):203–210. doi:10.1111/j.1600-0536.2007.01179.x
  • Thyssen JP, Johansen JD, Linneberg A, Menne T. The epidemiology of hand eczema in the general population–prevalence and main findings. Contact Dermatitis. 2010;62(2):75–87. doi:10.1111/j.1600-0536.2009.01669.x
  • Coenraads PJ. Hand eczema. N Engl J Med. 2012;367(19):1829–1837. doi:10.1056/NEJMcp1104084
  • Schuttelaar ML, Coenraads PJ, Huizinga J, De Monchy JG, Vermeulen KM. Increase in vesicular hand eczema after house dust mite inhalation provocation: a double-blind, placebo-controlled, cross-over study. Contact Dermatitis. 2013;68(2):76–85. doi:10.1111/j.1600-0536.2012.02172.x
  • Agner T, Andersen KE, Brandao FM, et al. Hand eczema severity and quality of life: a cross-sectional, multicentre study of hand eczema patients. Contact Dermatitis. 2008;59(1):43–47. doi:10.1111/j.1600-0536.2008.01362.x
  • Cvetkovski RS, Zachariae R, Jensen H, Olsen J, Johansen JD, Agner T. Quality of life and depression in a population of occupational hand eczema patients. Contact Dermatitis. 2006;54(2):106–111. doi:10.1111/j.0105-1873.2006.00783.x
  • Skoet R, Zachariae R, Agner T. Contact dermatitis and quality of life: a structured review of the literature. Br J Dermatol. 2003;149(3):452–456. doi:10.1046/j.1365-2133.2003.05601.x
  • Agner T, Elsner P. Hand eczema: epidemiology, prognosis and prevention. J Eur Acad Dermatol Venereol. 2020;34(Suppl 1):4–12. doi:10.1111/jdv.16061
  • Kang YC, Lee S, Ahn SK, Choi EH. Clinical manifestations of hand eczema compared by etiologic classification and irritation reactivity to SLS. J Dermatol. 2002;29(8):477–483. doi:10.1111/j.1346-8138.2002.tb00312.x
  • Svensson A. Hand eczema: an evaluation of the frequency of atopic background and the difference in clinical pattern between patients with and without atopic dermatitis. Acta Derm Venereol. 1988;68(6):509–513.
  • Coenraads P-J. Hand eczema is common and multifactorial. J Investig Dermatol. 2007;127(7):1568–1570. doi:10.1038/sj.jid.5700781
  • Veien NK, Hattel T, Laurberg G. Hand eczema: causes, course, and prognosis I. Contact Dermatitis. 2008;58(6):330–334. doi:10.1111/j.1600-0536.2008.01345.x
  • Wollenberg A, Blauvelt A, Guttman‐Yassky E, et al. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled Phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2020. doi:10.1111/bjd.19574
  • Dhingra N, Shemer A, Correa da Rosa J, et al. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J Allergy Clin Immunol. 2014;134(2):362–372. doi:10.1016/j.jaci.2014.03.009
  • Molin S, Diepgen TL, Ruzicka T, Prinz JC. Diagnosing chronic hand eczema by an algorithm: a tool for classification in clinical practice. Clin Exp Dermatol. 2011;36(6):595–601. doi:10.1111/j.1365-2230.2010.04001.x
  • Svensson A. Hand eczema: an evaluation of the frequency of atopic background and the difference in clinical pattern between patients with and without atopic dermatitis. Acta Derm Venereol. 1988;68(6):509.
  • Abramovits W, Stevenson LC. Atopic profiles, familial histories, and coexisting conditions associated with hand eczema. Skinmed. 2005;4(4):204–210. doi:10.1111/j.1540-9740.2005.03635.x
  • Coenraads PJ, Diepgen TL. Risk for hand eczema in employees with past or present atopic dermatitis. Int Arch Occup Environ Health. 1998;71(1):7–13. doi:10.1007/s004200050243
  • Belsito DV. Occupational contact dermatitis: etiology, prevalence, and resultant impairment/disability. J Am Acad Dermatol. 2005;53(2):303–313. doi:10.1016/j.jaad.2005.02.045
  • Leonard A, Guttman-Yassky E. The unique molecular signatures of contact dermatitis and implications for treatment. Clin Rev Allergy Immunol. 2019;56(1):1–8. doi:10.1007/s12016-018-8685-0
  • Gittler JK, Krueger JG, Guttman-Yassky E. Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis. J Allergy Clin Immunol. 2013;131(2):300–313. doi:10.1016/j.jaci.2012.06.048
  • DeJongh CM, John SM, Bruynzeel DP, et al. Cytokine gene polymorphisms and susceptibility to chronic irritant contact dermatitis. Contact Dermatitis. 2008;58(5):269–277. doi:10.1111/j.1600-0536.2008.01317.x
  • Ungar B, Correa da Rosa J, Shemer A, et al. Patch testing of food allergens promotes Th17 and Th2 responses with increased IL-33: a pilot study. Exp Dermatol. 2017;26(3):272–275. doi:10.1111/exd.13148
  • Molin S, Merl J, Dietrich KA, et al. The hand eczema proteome: imbalance of epidermal barrier proteins. Br J Dermatol. 2015;172(4):994–1001. doi:10.1111/bjd.13418
  • Wang X, Ye L, Lai Q, et al. Altered epidermal permeability barrier function in the uninvolved skin supports a role of epidermal dysfunction in the pathogenesis of occupational hand eczema. Skin Pharmacol Physiol. 2020;33(2):94–101. doi:10.1159/000506425
  • De Benedetto A, Rafaels NM, McGirt LY, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 2011;127(3):773–777. doi:10.1016/j.jaci.2010.10.018
  • Cork MJ, Robinson DA, Vasilopoulos Y, et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol. 2006;118(1):3–21; quiz 22–23. doi:10.1016/j.jaci.2006.04.042
  • Tauber M, Berard E, Lourari S, et al. Latent class analysis categorizes chronic hand eczema patients according to skin barrier impairment. J Eur Acad Dermatol Venereol. 2020;34(7):1529–1535. doi:10.1111/jdv.16083
  • Barrett A, Hahn-Pedersen J, Kragh N, Evans E, Gnanasakthy A. Patient-reported outcome measures in atopic dermatitis and chronic hand eczema in adults. Patient. 2019;12(5):445–459. doi:10.1007/s40271-019-00373-y
  • Diepgen TL, Andersen KE, Brandao FM, et al. Hand eczema classification: a cross-sectional, multicentre study of the aetiology and morphology of hand eczema. Br J Dermatol. 2009;160(2):353–358. doi:10.1111/j.1365-2133.2008.08907.x
  • Thyssen JP, Silverberg JI, Guttman-Yassky E. Chronic hand eczema understanding has ramifications on clinical management. J Eur Acad Dermatol Venereol. 2020;34(8):e429–e430. doi:10.1111/jdv.16375
  • Christoffers WA, Coenraads PJ, Svensson A, et al. Interventions for hand eczema. Cochrane Database Syst Rev. 2019;4:CD004055. doi:10.1002/14651858.CD004055.pub2
  • Worm M, Bauer A, Elsner P, Mahler V, Molin S, Nielsen T. Topical delgocitinib is an efficacious and well tolerated treatment for patients with chronic hand eczema: 8467. J Am Acad Dermatol. 2019;81(4).
  • Worm M, Bauer A, Elsner P, Mahler V, Molin S, Nielsen TSS. Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study. Br J Dermatol. 2020;182(5):1103–1110. doi:10.1111/bjd.18469
  • Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. 2019;10:2847. doi:10.3389/fimmu.2019.02847
  • Safety and efficacy of ARQ-252 cream in subjects with chronic hand eczema. Available from: https://ClinicalTrials.gov/show/NCT04378569. Accessed December 21, 2020.
  • A study for a topical medication versus placebo in patients with hand dermatitis. Available from: https://ClinicalTrials.gov/show/NCT03703895. Accessed December 21, 2020.
  • Yang M, Chang JM. Successful treatment of refractory chronic hand eczema with calcipotriol/betamethasone ointment: a report of three cases. Exp Ther Med. 2015;10(5):1943–1946. doi:10.3892/etm.2015.2729
  • Gola M, Milanesi N, D’Erme AM. Clinical evaluation and assessment of the therapeutic efficacy of alitretinoin in a group of patients with chronic hand eczema refractory to topical steroid therapy. G Ital Dermatol Venereol. 2014;149(4):435–439.
  • Ham K, Maini P, Gooderham MJ. Real-world experience with alitretinoin in a community dermatology practice setting in patients with chronic hand dermatitis. J Cutan Med Surg. 2014;18(5):332–336. doi:10.2310/7750.2014.13195
  • Christoffers WA, Politiek K, Coenraads PJ, van der Schaft J, de Bruin-weller MS, Schuttelaar ML. Drug survival of cyclosporine in the treatment of hand eczema: a multicentre, daily use study. J Eur Acad Dermatol Venereol. 2016;30(1):63–66. doi:10.1111/jdv.13057
  • Granlund H, Erkko P, Eriksson E, Reitamo S. Comparison of cyclosporine and topical betamethasone-17,21-dipropionate in the treatment of severe chronic hand eczema. Acta Derm Venereol. 1996;76(5):371–376. doi:10.2340/0001555576371376
  • Gooderham M, Lynde CW, Papp K, et al. Review of systemic treatment options for adult atopic dermatitis. J Cutan Med Surg. 2017;21(1):31–39. doi:10.1177/1203475416670364
  • Oosterhaven JA, Politiek K, Schuttelaar MA. Azathioprine treatment and drug survival in patients with chronic hand eczema - results from daily practice. Contact Dermatitis. 2017;76(5):304–307. doi:10.1111/cod.12691
  • Oosterhaven JAF, Voorberg AN, Romeijn GLE, de Bruin-weller MS, Schuttelaar MLA. Effect of dupilumab on hand eczema in patients with atopic dermatitis: an observational study. J Dermatol. 2019;46(8):680–685. doi:10.1111/1346-8138.14982
  • Asana biosciences announces positive topline results from phase 2b study of oral JAK/SYK inhibitor gusacitinib (ASN002) in patients with chronic hand eczema: rapid and significant improvement demonstrated [press release]. Business Wire. 2020.
  • Loman L, Diercks GFH, Schuttelaar MLA. Three cases of non-atopic hyperkeratotic hand eczema treated with dupilumab. Contact Dermatitis. 2020. doi:10.1111/cod.13693
  • Oosterhaven JAF, Romeijn GLE, Schuttelaar MLA. Dupilumab treatment of very severe refractory atopic hand eczema. JAMA Dermatol. 2018;154(8):969–970. doi:10.1001/jamadermatol.2018.2027
  • Study to evaluate ASN002 in subjects with moderate to severe chronic hand eczema. Available from: https://ClinicalTrials.gov/show/NCT03728504. Accessed December 21, 2020.
  • Pavel AB, Song T, Kim HJ, et al. Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144:1011–1024. doi:10.1016/j.jaci.2019.07.013
  • Efficacy and safety of dupilumab chronic hands eczema refractory to highly potent topical corticosteroids. Available from: https://ClinicalTrials.gov/show/NCT03861455. Accessed December 21, 2020.
  • Zirwas MJ. Dupilumab for hand eczema. J Am Acad Dermatol. 2018;79(1):167–169. doi:10.1016/j.jaad.2018.02.073
  • Egawa K. Topical vitamin D3 derivatives in treating hyperkeratotic palmoplantar eczema: a report of five patients. J Dermatol. 2005;32(5):381–386. doi:10.1111/j.1346-8138.2005.tb00911.x
  • Juntongjin P, Pongprasert R. Calcipotriol ointment shows comparable efficacy to topical steroids in chronic hand eczema. Dermatol Ther. 2019;32(4):e12956. doi:10.1111/dth.12956
  • Pongprasert R, Juntongjin P. Calcipotriol: a promising treatment for hand eczema. 2017.
  • Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol. 2002;46(2):228–241. doi:10.1067/mjd.2002.120942
  • Wollina U. The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. Am J Clin Dermatol. 2007;8(3):157–173. doi:10.2165/00128071-200708030-00003
  • Warshaw EM. Therapeutic options for chronic hand dermatitis. Dermatol Ther. 2004;17(3):240–250. doi:10.1111/j.1396-0296.2004.04025.x
  • Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology. 2005;211(2):174–187. doi:10.1159/000086739
  • Belsito DV, Fowler JF, Marks JG, et al. Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis. 2004;73(1):31–38.
  • Wellington K, Jarvis B. Topical pimecrolimus. Drugs. 2002;62(5):817–840. doi:10.2165/00003495-200262050-00007
  • Pimecrolimus cream 1% in patients (18 years of age and over) with mild to moderate chronic hand dermatitis. Available from: https://ClinicalTrials.gov/show/NCT00226707. Accessed December 21, 2020.
  • Schliemann S, Kelterer D, Bauer A, et al. Tacrolimus ointment in the treatment of occupationally induced chronic hand dermatitis. Contact Dermatitis. 2008;58(5):299–306. doi:10.1111/j.1600-0536.2007.01314.x
  • Thelmo MC, Lang W, Brooke E, et al. An open-label pilot study to evaluate the safety and efficacy of topically applied tacrolimus ointment for the treatment of hand and/or foot eczema. J Dermatolog Treat. 2003;14(3):136–140. doi:10.1080/09546630310009491
  • Gabros S, Nessel TA, Zito PM. Topical corticosteroids. In: StatPearls. Treasure Island (FL); 2020.
  • Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4(37):1–191. doi:10.3310/hta4370
  • Perry AD, Trafeli JP. Hand dermatitis: review of etiology, diagnosis, and treatment. J Am Board Fam Med. 2009;22(3):325–330. doi:10.3122/jabfm.2009.03.080118
  • English J, Aldridge R, Gawkrodger DJ, et al. Consensus statement on the management of chronic hand eczema. Clin Exp Dermatol. 2009;34(7):761–769. doi:10.1111/j.1365-2230.2009.03649.x
  • Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician. 2009;79(2):135–140.
  • Study to evaluate safety, efficacy and tolerability of clobetasol propionate for chronic hand dermatitis. Available from: https://ClinicalTrials.gov/show/NCT00828464. Accessed December 21, 2020.
  • Kircik LH, Tropmann C. Treatment of mild-to-moderate chronic hand dermatitis with clobetasol propionate 0.05% EF foam: results from an open-label study. J Drugs Dermatol. 2011;10(12):1398–1402.
  • Safety and efficacy study of triamcinolone acetonide durapeel to treat hand dermatitis. Available from: https://ClinicalTrials.gov/show/NCT00890968. Accessed December 21, 2020.
  • Cohen DE, Heidary N. Treatment of irritant and allergic contact dermatitis. Dermatol Ther. 2004;17(4):334–340. doi:10.1111/j.1396-0296.2004.04031.x
  • Chen Y, Wang X, Zhang C, Shi W. Detection and treatment of Staphylococcus aureus colonization in chronic hand eczema: a multicenter study. J Dermatolog Treat. 2019;30(6):565–567. doi:10.1080/09546634.2018.1476650
  • Wang X, Xu W, Chen Y, et al. Staphylococcus aureus colonization and chronic hand eczema: a multicenter clinical trial. Arch Dermatol Res. 2019;311(7):513–518. doi:10.1007/s00403-019-01924-x
  • Microbial colonization and change of chronic keratinized hand eczema after using halometasone triclosan. Available from: https://ClinicalTrials.gov/show/NCT03246776. Accessed December 21, 2020.
  • Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy and Clin Immunol. 2017;140(3):633–643. doi:10.1016/j.jaci.2017.07.006
  • Soeberdt M, Kilic A, Abels C. Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis. Eur J Pharmacol. 2020;881:173242. doi:10.1016/j.ejphar.2020.173242
  • Vávrová K. Emerging small-molecule compounds for treatment of atopic dermatitis: a review. Expert Opin Ther Pat. 2016;26(1):21–34. doi:10.1517/13543776.2016.1101451
  • Hoppmann J, Baumer W, Galetzka C, Hofgen N, Kietzmann M, Rundfeldt C. The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005;57(12):1609–1617. doi:10.1211/jpp.57.12.0011
  • Elsner P, Agner T. Hand eczema: treatment. J Eur Acad Dermatol Venereol. 2020;34(Suppl 1):13–21. doi:10.1111/jdv.16062
  • Proof of concept, twice daily applications of LEO 124249 ointment in the treatment of chronic hand eczema. Available from: https://ClinicalTrials.gov/show/NCT02664805. Accessed December 21, 2020.
  • Phase 2b dose-ranging trial to evaluate delgocitinib cream 1, 3, 8, and 20 mg/g compared to delgocitinib cream vehicle over a 16-week treatment period in adult subjects with chronic hand eczema. Available from: https://ClinicalTrials.gov/show/NCT03683719. Accessed December 21, 2020.
  • Diaz A, Guttman-Yassky E. Topical agents for the treatment of atopic dermatitis. Expert Rev Clin Immunol. 2019;15(4):369–382. doi:10.1080/1744666X.2019.1564038
  • Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol. 1996;107(1):51–56. doi:10.1111/1523-1747.ep12297888
  • Sakkas I, Mavropoulos A, Bogdanos D. Phosphodiesterase 4 inhibitors in immune-mediated diseases: mode of action, clinical applications, current and future perspectives. Curr Med Chem. 2017;24(28):3054–3067. doi:10.2174/0929867324666170530093902
  • Kofoed K, Skov L, Zachariae C. New drugs and treatment targets in psoriasis. Acta Derm Venereol. 2015;95(2):133–139. doi:10.2340/00015555-1931
  • Yang H, Wang J, Zhang X, et al. Application of topical phosphodiesterase 4 inhibitors in mild to moderate atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(5):585–593. doi:10.1001/jamadermatol.2019.0008
  • Arcutis completes enrollment in phase 1/2b study evaluating ARQ-252 in chronic hand eczema [press release]. Westlake Village, CA. 2020.
  • Nedoszytko B, Sokolowska-Wojdylo M, Ruckemann-Dziurdzinska K, Roszkiewicz J, Nowicki RJ. Chemokines and cytokines network in the pathogenesis of the inflammatory skin diseases: atopic dermatitis, psoriasis and skin mastocytosis. Postepy Dermatol Alergol. 2014;2(2):84–91. doi:10.5114/pdia.2014.40920
  • Ouwehand K, Scheper RJ, de Gruijl TD, Gibbs S. Epidermis-to-dermis migration of immature Langerhans cells upon topical irritant exposure is dependent on CCL2 and CCL5. Eur J Immunol. 2010;40(7):2026–2034. doi:10.1002/eji.200940150
  • Lee HY, Stieger M, Yawalkar N, Kakeda M. Cytokines and chemokines in irritant contact dermatitis. Mediators Inflamm. 2013;2013:916497. doi:10.1155/2013/916497
  • Van de Kerkhof P, De Hoop D, De Korte J, Cobelens S, Kuipers M. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology. 2000;200(4):292–298. doi:10.1159/000018390
  • Rodgers M, Griffin S, Paulden M, et al. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal. Pharmacoeconomics. 2010;28(5):351–362. doi:10.2165/11532160-000000000-00000
  • Politiek K, Christoffers WA, Coenraads PJ, Schuttelaar MA. Alitretinoin and acitretin in severe chronic hand eczema; results from a retrospective daily practice study. Dermatol Ther. 2016;29(5):364–371. doi:10.1111/dth.12362
  • Shi VY, Sivamani RK, Maibach H. Alitretinoin for the treatment of chronic hand eczema: clinical rationale. Clin Investig (Lond). 2014;4(8):763–773. doi:10.4155/cli.14.58
  • Nada HR, Rashed LA, Elantably DMM, El Sharkawy DA. Expression of retinoid receptors in hand eczema. Int J Dermatol. 2020;59(5):576–581. doi:10.1111/ijd.14830
  • Ruzicka T, Lynde CW, Jemec GB, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008;158(4):808–817. doi:10.1111/j.1365-2133.2008.08487.x
  • Bissonnette R, Worm M, Gerlach B, et al. Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema. Br J Dermatol. 2010;162(2):420–426. doi:10.1111/j.1365-2133.2009.09572.x
  • Diepgen TL, Pfarr E, Zimmermann T. Efficacy and tolerability of alitretinoin for chronic hand eczema under daily practice conditions: results of the TOCCATA open study comprising 680 patients. Acta Derm Venereol. 2012;92(3):251–255. doi:10.2340/00015555-1256
  • Schindler M, Drozdenko G, Kuhl AA, Worm M. Immunomodulation in patients with chronic hand eczema treated with oral alitretinoin. Int Arch Allergy Immunol. 2014;165(1):18–26. doi:10.1159/000365659
  • Fowler JF, Graff O, Hamedani AG. A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of alitretinoin (BAL4079) in the treatment of severe chronic hand eczema refractory to potent topical corticosteroid therapy. J Drugs Dermatol. 2014;13(10):1198–1204.
  • Cheng C, Michaels J, Scheinfeld N. Alitretinoin: a comprehensive review. Expert Opin Investig Drugs. 2008;17(3):437–443. doi:10.1517/13543784.17.3.437
  • Blair HA, Scott LJ. Alitretinoin: a review in severe chronic hand eczema. Drugs. 2016;76(13):1271–1279. doi:10.1007/s40265-016-0621-0
  • Ingram JR, Batchelor JM, Williams HC. Alitretinoin as a potential advance in the management of severe chronic hand eczema. Arch Dermatol. 2009;145(3):314–315. doi:10.1001/archdermatol.2008.608
  • Dirschka T, Reich K, Bissonnette R, Maares J, Brown T, Diepgen T. An open‐label study assessing the safety and efficacy of alitretinoin in patients with severe chronic hand eczema unresponsive to topical corticosteroids. Clin Exp Dermatol. 2011;36(2):149–154. doi:10.1111/j.1365-2230.2010.03955.x
  • Gola M, Milanesi N, Derme A. Clinical evaluation and assessment of the therapeutic efficacy of alitretinoin in a group of patients with chronic hand eczema refractory to topical steroid therapy. G Ital Dermatol Venereol. 2014;149(4):435–439.
  • Morris M, Schifano L, Fong R, Graff O. Safety of alitretinoin for severe refractory chronic hand eczema: clinical studies and postmarketing surveillance. J Dermatol Treat. 2016;27(1):54–58. doi:10.3109/09546634.2015.1034080
  • Tan J, Maari C, Nigen S, Bolduc C, Bissonnette R. Open-label exploratory study of acitretin for the treatment of severe chronic hand dermatitis. J Dermatolog Treat. 2015;26(4):373–375. doi:10.3109/09546634.2014.952608
  • Thestrup-Pedersen K, Andersen KE, Menne T, Veien NK. Treatment of hyperkeratotic dermatitis of the palms (eczema keratoticum) with oral acitretin. A single-blind placebo-controlled study. Acta Derm Venereol. 2001;81(5):353–355. doi:10.1080/000155501317140089
  • Song M, Lee HJ, Lee WK, et al. Acitretin as a therapeutic option for chronic hand eczema. Ann Dermatol. 2017;29(3):385–387. doi:10.5021/ad.2017.29.3.385
  • Pilot study on the use of acitretin for the treatment of severe chronic hand dermatitis. Available from: https://ClinicalTrials.gov/show/NCT01545284. Accessed December 21, 2020.
  • Alitretinoin vs cyclosporine in severe recurrent vesicular hand eczema. Available from: https://ClinicalTrials.gov/show/NCT03026946. Accessed December 21, 2020.
  • Alitretinoin vs azathioprine in severe non-hyperkeratotic hand eczema. Available from: https://ClinicalTrials.gov/show/NCT03026907. Accessed December 21, 2020.
  • Brandt C, Pavlovic V, Radbruch A, Worm M, Baumgrass R. Low‐dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis. Allergy. 2009;64(11):1588–1596. doi:10.1111/j.1398-9995.2009.02054.x
  • Khattri S, Shemer A, Rozenblit M, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy and Clin Immunol. 2014;133(6):1626–1634. doi:10.1016/j.jaci.2014.03.003
  • Schram ME, Roekevisch E, Leeflang MMG, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy and Clin Immunol. 2011;128(2):353–359. doi:10.1016/j.jaci.2011.03.024
  • Waxweiler WT, Agans R, Morrell DS. Systemic treatment of pediatric atopic dermatitis with azathioprine and mycophenolate mofetil. Pediatr Dermatol. 2011;28(6):689–694. doi:10.1111/j.1525-1470.2011.01488.x
  • Caufield M, Tom WL. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. J Am Acad Dermatol. 2013;68(1):29–35. doi:10.1016/j.jaad.2012.07.001
  • Bianchi L, Del Duca E, Romanelli M, Saraceno R, Chimenti S, Chiricozzi A. Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis. Expert Opin Drug Metab Toxicol. 2016;12(9):1121–1128. doi:10.1080/17425255.2016.1206886
  • Dattola A, Del Duca E, Saraceno R, Gramiccia T, Bianchi L. Safety evaluation of apremilast for the treatment of psoriasis. Expert Opin Drug Saf. 2017;16(3):381–385. doi:10.1080/14740338.2017.1288714
  • Zerilli T, Ocheretyaner E. Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. Pharm Therap. 2015;40(8):495.
  • Abrouk M, Farahnik B, Zhu TH, et al. Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses. J Am Acad Dermatol. 2017;77(1):177–180. doi:10.1016/j.jaad.2017.03.020
  • Navarro-Trivino FJ, Cuenca-Barrales C, Vega-Castillo JJ, Ruiz-Villaverde R. Chronic hand eczema and hepatogenic pruritus with good response to apremilast. Dermatol Ther. 2019;32(3):e12879. doi:10.1111/dth.12879
  • Ghosh N, Nasrin T, Mahmud H, Paul HK. Efficacy and safety of low dose Methotrexate in the treatment of chronic hand eczema. J Pak Assoc Dermatol. 2020;30(1):3–8.
  • Shaffrali FC, Colver GB, Messenger AG, Gawkrodger DJ. Experience with low-dose methotrexate for the treatment of eczema in the elderly. J Am Acad Dermatol. 2003;48(3):417–419. doi:10.1067/mjd.2003.137
  • Egan CA, Rallis TM, Meadows KP, Krueger GG. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol. 1999;40(4):612–614. doi:10.1016/S0190-9622(99)70446-9
  • Apfelbacher CJ, Ofenloch RF, Weisshaar E, et al. Chronic hand eczema in Germany: 5‐year follow‐up data from the CARPE registry. Contact Dermatitis. 2019;80(1):45–53. doi:10.1111/cod.13113
  • O’Shea PM, Lugo-Somolinos A Methotrexate versus acitretin in the treatment of chronic hand dermatitis. 2015.
  • Politiek K, van der Schaft J, Christoffers WA, et al. Drug survival of methotrexate treatment in hand eczema patients: results from a retrospective daily practice study. J Eur Acad Dermatol Venereol. 2016;30(8):1405–1407. doi:10.1111/jdv.13253
  • Sideris N, Vakirlis E, Tsentemeidou A, Kourouklidou A, Ioannides D, Sotiriou E. Under development JAK inhibitors for dermatologic diseases. Mediterr J Rheumatol. 2020;31(Suppl 1):137–144. doi:10.31138/mjr.31.1.137
  • Szilveszter KP, Németh T, Mócsai A. Tyrosine kinases in autoimmune and inflammatory skin diseases. Front Immunol. 2019;10:1862. doi:10.3389/fimmu.2019.01862
  • He H, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):181–192. doi:10.1007/s40257-018-0413-2
  • Montilla AM, Gómez-García F, Gómez-Arias PJ, et al. Scoping review on the use of drugs targeting JAK/STAT pathway in atopic dermatitis, vitiligo, and alopecia areata. Dermatol Ther (Heidelb). 2019;1–29.
  • Singh R, Heron CE, Ghamrawi RI, Strowd LC, Feldman SR. Emerging role of janus kinase inhibitors for the treatment of atopic dermatitis. ImmunoTargets Ther. 2020;9:255. doi:10.2147/ITT.S229667
  • Szalus K, Trzeciak M, Nowicki RJJAK-STAT. Inhibitors in atopic dermatitis from pathogenesis to clinical trials results. Microorganisms. 2020;8(11):1743. doi:10.3390/microorganisms8111743
  • Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155–172. doi:10.1016/j.jaci.2018.08.022
  • Hendricks AJ, Yosipovitch G, Shi VY. Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review. J Dermatolog Treat. 2019;1–10.
  • Seegraber M, Srour J, Walter A, Knop M, Wollenberg A. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018;11(5):467–474. doi:10.1080/17512433.2018.1449642
  • Soria A, Du-Thanh A, Seneschal J, et al. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155:1312. doi:10.1001/jamadermatol.2019.2613
  • Lee DE, Clark AK, Tran KA, Shi VY. New and emerging targeted systemic therapies: a new era for atopic dermatitis. J Dermatolog Treat. 2018;29(4):364–374. doi:10.1080/09546634.2017.1373736
  • Kuznik A, Bego-Le-Bagousse G, Eckert L, et al. Economic evaluation of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults. Dermatol Ther (Heidelb). 2017;7(4):493–505. doi:10.1007/s13555-017-0201-6
  • Sonya Kahn M, Rind D, Chapman R, Kumar V, Kahn S, Carlson J. Economic evaluation of dupilumab for moderate-to-severe atopic dermatitis: a cost-utility analysis. J Drugs Dermatol. 2018;17(7):750–756.
  • Van Coevorden AM, Coenraads PJ, Svensson A, et al. Overview of studies of treatments for hand eczema-the EDEN hand eczema survey. Br J Dermatol. 2004;151(2):446–451. doi:10.1111/j.1365-2133.2004.06040.x
  • Veien NK, Olholm Larsen P, Thestrup-Pedersen K, Schou G. Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. Br J Dermatol. 1999;140(5):882–886. doi:10.1046/j.1365-2133.1999.02819.x
  • Rademaker M, Armour K, Baker C, et al. Management of chronic hand and foot eczema. An Australia/New Zealand Clinical narrative. Australas J Dermatol. 2020. doi:10.1111/ajd.13418
  • LEO 19123 cream in the treatment of hand eczema. Available from: https://ClinicalTrials.gov/show/NCT00404196. Accessed December 21, 2020.
  • A randomised trial of a moisturising cream in preventing recurrence of hand eczema. Available from: https://ClinicalTrials.gov/show/NCT00576550. Accessed December 21, 2020.
  • Blank PR, Blank AA, Szucs TD. Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema-a long-term analysis from a Swiss perspective. BMC Dermatol. 2010;10(1):4. doi:10.1186/1471-5945-10-4
  • King T, McKenna J, Alexandroff AB. Alitretinoin for the treatment of severe chronic hand eczema. Patient Prefer Adherence. 2014;8:1629–1634. doi:10.2147/PPA.S38830
  • Reich A, Wilke A, Gediga G, et al. Health education decreases incidence of hand eczema in metal work apprentices: results of a controlled intervention study. Contact Dermatitis. 2020;82(6):350–360. doi:10.1111/cod.13502
  • Wang B, Liu -L-L, Zhao Z-T, Tu P. Impaired skin barrier function and downregulated expression of caspase-14 in moderate to severe chronic hand eczema. Dermatology. 2018;234(5–6):180–185. doi:10.1159/000489701
  • Dyjack N, Goleva E, Rios C, et al. Minimally invasive skin tape strip RNA sequencing identifies novel characteristics of the type 2–high atopic dermatitis disease endotype. J Allergy and Clin Immunol. 2018;141(4):1298–1309. doi:10.1016/j.jaci.2017.10.046
  • Guttman-Yassky E, Diaz A, Pavel AB, et al. Use of tape strips to detect immune and barrier abnormalities in the skin of children with early-onset atopic dermatitis. JAMA Dermatol. 2019;155(12):1358–1370. doi:10.1001/jamadermatol.2019.2983
  • He H, Bissonnette R, Wu J, et al. Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. J Allergy and Clin Immunol. 2020. doi:10.1016/j.jaci.2020.05.048
  • Loesche C, Kolbinger F, Valentin M-A, et al. Interleukin-17A blockade with secukinumab results in decreased neutrophil infiltration in psoriasis: minimally-invasive measurement by tape stripping. Adv Precision Med. 2016;1:1–9. doi:10.18063/APM.2016.02.003